glp-1 through ro Launches Wegovy® Pill Integration with Novo Nordisk Ro launches GLP-1 supply tracker

Month 3 stabilizes around 8-15 total pounds lost, with the trajectory becoming clearer: fast responders exceed this, while gradual responders hit this range by month 4-6

The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus

Oral GLP-1 weight loss medication Orfoglipron (Eli Lilly) is nearing an FDA decision with available expect mid-2026 Clinical trials show meaningful results: 12-16% 1,2 average weight loss, which is slightly less than injectables Side effects are similar: mostly gastrointestinal, such as nausea or diarrhea, typically improving over 23 months

These risks have become a key focus in the growing number of Wegovy-related lawsuits